Commercial stage pharmaceutical company Shield Therapeutics plc (LSE: STX) announced on Wednesday that it has entered into a USD5.7m milestone monetisation agreement with AOP Health International Management AG, its largest shareholder with a 39.8% stake. AOP's founder, Dr Rudolf Widmann, will join Shield's board as a non-executive director with immediate effect.
Under the agreement, AOP will provide Shield with USD5.7m in cash for the right to receive the USD11.4m China approval milestone payment from Jiangsu Aosaikang Pharmaceutical Co, Ltd. (ASK Pharma), Shield's commercial partner in China. ASK Pharma is conducting a Phase 3 study expected to complete by late 2024, with potential milestone payment by 2026 upon successful completion and regulatory approval.
If the milestone is not achieved by 31 December 2026 or if the agreement is terminated, Shield must repay the advance with interest (SOFR + 9.25%) and an exit fee of 6.5%. The advance is secured by AOP's right to the milestone payment.
The transaction is considered a related party transaction under AIM Rules due to AOP's substantial shareholding. Shield's directors, after consulting Peel Hunt LLP, believe the agreement terms are fair to shareholders.
Dr Rudolf Widmann, a veteran pharmaceutical scientist and entrepreneur, founded AOP Health in 1996. He holds degrees in pharmacy and pharmacology from the University of Innsbruck and has no direct shareholding in Shield. As a non-executive director, Dr Widmann will receive a base fee of GBP40,000, with additional fees for any board committee chairmanships, and is not eligible for the company's incentive arrangements.
Shield's Accrufer/Feraccru (ferric maltol) addresses unmet needs in iron deficiency treatment. It is FDA-approved and marketed in the US through Viatris Inc, with various licensing agreements for international markets, including China, Europe, Australia, New Zealand, South Korea and Canada.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA